Darusentan

Drug Profile

Darusentan

Alternative Names: HMR 4005; LU-135252

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Abbott GmbH & Co. KG
  • Developer Gilead Sciences
  • Class Antihypertensives; Heart failure therapies; Phenylpropionates; Pyrimidines; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Arrhythmias; Diabetic angiopathies; Diabetic nephropathies; Heart failure; Ischaemic heart disorders; Renal transplant rejection; Resistant hypertension; Stroke

Most Recent Events

  • 17 Dec 2009 Final efficacy data from a phase III (DAR-312) trial in Resistant hypertension released by Gilead Sciences
  • 16 Sep 2009 Final safety and efficacy data from a phase III (DAR-311) trial in Resistant hypertension released by Gilead Sciences
  • 08 Apr 2009 Preliminary safety and efficacy data from a phase III (DAR-311) trial in Resistant hypertension released by Gilead Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top